Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein Hox-D10 is a sequence-specific transcription factor in the Abd-B homeobox family, encoded by the HOXD10 gene on chromosome 2. It is expressed in developing limb buds and plays a critical role in positional identity during development, limb differentiation, and tissue patterning[1][2][3]. HOXD10 acts as a tumor suppressor that limits cell migration, invasion, and angiogenesis. Its downregulation, often via microRNAs (like miR-10b), is linked to increased tumor invasiveness and metastasis across a range of cancers including glioblastoma, breast, gastric, ovarian, and bladder carcinomas[3]. In addition to oncological associations, mutations or loss of function of HOXD10 can cause congenital malformations such as Wilms’ tumor and congenital vertical talus[1][2][3]. HOXD10 is being investigated as a prognostic biomarker and potential therapeutic target for multiple malignancies, but currently, there are no direct clinical drugs targeting HOXD10[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Homeobox protein Hox-D10 (HOXD10).